Industry
Biotechnology
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Insights
February 28, 2024 | 11:24 am
Portfolio Pulse from Benzinga Newsdesk
December 14, 2023 | 9:23 pm
Portfolio Pulse from Benzinga Insights
November 17, 2023 | 9:31 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2023 | 11:17 am
Portfolio Pulse from Benzinga Insights
September 28, 2023 | 9:31 pm
Portfolio Pulse from Lisa Levin
August 18, 2023 | 3:08 pm
Portfolio Pulse from Benzinga Newsdesk
August 04, 2023 | 1:48 pm
Portfolio Pulse from Benzinga Newsdesk
August 04, 2023 | 10:47 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.